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Abstract
Background: Alongside specialist cancer clinics, general practitioners have an important role in cancer patients’ follow-up care, yet no
literature summarises the nature, extent and impact of their involvement. This paper addresses this issue through a review of the literature.
Methods: Studies were sourced from six academic databases - AustHealth (n = 202), CINAHL (n = 500), the Cochrane Library (reviews
and trials; n = 200), Embase (n = 368), PHCRIS (n = 132) and PubMed/Medline (n = 410). Studies that focused on interventions designed
for patients receiving follow-up care and reported cancer care provided by a general practitioner delivered alongside specialist care were
reviewed.
Results: A total of 19 papers were identified as relevant for this review (3 randomised control trials; 4 cross-sectional, 5 cohort and 3
qualitative studies, and 3 systematic reviews). The reviewed studies indicated that providing general practitioner-led supportive interventions for post-treatment care of cancer patients is feasible and acceptable to patients. General practitioner involvement resulted in
improved physical and psychosocial well-being of patients and continuity of care, especially for patients with concomitant health
conditions.
Conclusion: Involving general practitioners in post-treatment cancer care is beneficial to patients. However, proactive initiatives
that encourage and facilitate patients to consult their general practitioner about their needs or symptoms of recurrence should be
considered.
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Introduction
With improved survival of cancer patients following treatment, attention needs to be paid on the ongoing physical and
psychosocial needs of this population [1]. Long-term physical problems and psychological morbidity such as anxiety
[2], depression [3] and fear of recurrence [4], and [5,6] social factors such as financial problems [7] and activity limitation [6,8] continue to affect patients for many years following treatment.
Cancer patients are now living longer and many have co-existing health conditions [9,10]. For example, about 50%
of people with colorectal cancer are now living beyond 10 years after treatment [11] and between 30% and 60% of
colorectal cancer survivors aged 70 years or older have other concomitant health conditions and are more likely to
die of other causes [12]. As the survival of cancer patients improves, general practitioners will find that they occupy a
larger proportion of their practices. Many of the cancer patients will have other medical issues and supporting people
treated for cancer is going to become a significant feature of their practice. Also, with the increasing number of cancer patients accessing specialist cancer clinics, strategies that supplement these services will be required to support
patients with long-term treatment side effects.
In Australia, cancer patients attend a general practitioner for multiple reasons [10]. Patients visit general practitioners
for other health conditions and preventive health services such as screening, health promotion advice and vaccination [13]. Given that general practitioner services are a cornerstone of the Australian health system, there is potential
for general practitioners to support cancer patients along with ongoing specialist care. Moreover, there is evidence
that cancer patients first present to a general practitioner with cancer-related side effects or symptoms of recurrence,
even with ongoing management by their specialist [14].
There is empirical evidence that a general practitioner-led follow-up model for cancer patients would be a safe and
acceptable alternative to specialist follow-up especially for patients in remission [14]; however, oncologists still need
to play a fundamental role in the management of these patients [15,16]. Studies have shown that cancer patients
who are followed by both oncologists and general practitioners receive better preventive health and cancer care
compared to those who are managed by either of the specialities independently [13]. Also, some patients still value
access to specialist services, especially in the early stages after treatment [15,16].
To date, most of the literature reviews that report on interventions provided by a general practitioner concurrently with
the specialist only provide details regarding organisation of patient care and flow of information between the specialist and the general practitioner [17–20]. Although these reviews offer recommendations regarding communication
between the general practitioner and the specialist [18,19,21], patients’ outcome data regarding the issues
addressed during patient visits with the general practitioner are limited [17].
Given these findings and the potential benefits of support that patients may receive by having a general practitioner
involved in their cancer care, a literature review was conducted to assess care of patients in the context of ongoing
specialist care and with particular reference to general practitioner involvement. This review focused on all types of
cancer studies that met the inclusion criteria assessing integrated approaches to care for multiple cancer types.

Aims
The aims of this literature review were to:
. Critically appraise the selected studies
. Describe proactive management of patients with long-term needs following cancer treatment, including surveillance for recurrence
. Describe the effectiveness of general practitioner support in post-treatment cancer care

Methods
Search strategy
A search strategy was developed to electronically source studies published in English from six academic databases AustHealth, CINAHL, the Cochrane Online Library (reviews and trials), Embase, PHCRIS and PubMed/Medline.
These were searched in January 2014 employing the following strategies using Medical Subject Headings (MeSH):
. Family practice [mh] OR primary health care [mh] or general practice AND
. Parallel care as Topic [mh] OR shared care as Topic [mh] OR cancer follow-up* care [mh] AND

This article is published in a peer reviewed section of the International Journal of Integrated Care

2

International Journal of Integrated Care – Volume 15, 8 June – URN:NBN:NL:UI:10-1-114828 – http://www.ijic.org/

.
.
.
.

Evaluation research [mh]
Randomised control trial [mh]
Feasibility projects [mh]
Various combinations (1 AND 2; 1 AND 3 AND 4; 1 AND 5; 2 AND 3; 2 AND 4; 2 AND 5)

Eligibility of studies, types of participants and outcomes assessed
For inclusion, studies had to describe delivery of interventions by a general practitioner and care had to be
delivered alongside specialist care. Studies that included adult cancer patients regardless of the site or stage of
the disease were also eligible for review. For inclusion in the review, patients should have completed treatment
for cancer. Also, studies evaluating general practitioners and patients perspectives to cancer shared care were
included.
Since terms such as ‘shared care’, ‘complementary care’ and ‘parallel care’ were poorly standardised within the
taxonomy and nomenclature of the electronic databases, the search strategy was kept as wide as possible. All
papers in which such terms were stated were included in the review. In addition, the cancer follow-up phase was
poorly defined with regards to when this period began. Hence, all studies in which patients had completed the indicated treatment were included in the review.

Identification of studies
A total of 1802 papers were identified from the six academic databases - AustHealth (n = 202), CINAHL (n = 500),
the Cochrane Library (reviews and trials; n = 200), Embase (n = 368), PHCRIS (n = 132) and PubMed/Medline
(n = 410). Potentially relevant titles and abstracts of 533 references were reviewed using the following inclusion
criteria:
. Study represents a research article (rather than a letter or commentary)
. Research context is primary care, that is, settings in which health practitioners were primary health physicians, family practice
doctors or general practitioners
. Primary focus is to describe intervention(s) or evaluate care provided by a general practitioner alongside hospital care for
patients who have completed cancer treatment

Titles and abstracts of articles identified through database searching and hand searching of the reference lists (n =
1802) were evaluated for relevance by three researchers (IN, MJ and AM). Potentially relevant articles (n = 533)
were further subjected to a more detailed evaluation and 391 articles were excluded because they did not meet
the inclusion criteria. The first author (IN) and two other reviewers (MJ and AM) independently reviewed the remaining 142 studies, with studies that included other models of post-treatment cancer care being excluded (n =123). In
total, 19 studies were eligible to be included in the review.
Schematic representation of the selection process of the articles included in this review is shown in Figure 1.

Data extraction
One reviewer (IN) extracted articles and assessed the methodological quality of the studies using Consolidated
Standards of Reporting Trials (CONSORT) [22] for randomised control trials, STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) [23,24] for cohort and cross-sectional studies and Walsh and Downe criteria [25] for qualitative studies.
CONSORT is an evidence-based, minimum set of recommendations for reporting randomised control trials. It offers
a standard way for authors to prepare reports of trial findings, facilitating their complete and transparent reporting and
aiding their critical appraisal and interpretation. The CONSORT statement comprises a 25-item checklist. The checklist items focus on reporting how the trial was designed, analysed and interpreted [22].
STROBE stands for an international, collaborative initiative of epidemiologists, methodologists, statisticians,
researchers and journal editors involved in the conduct and dissemination of observational studies, with the common
aim of strengthening the reporting of observational studies in epidemiology. STROBE stipulates a standard way for
reporting study design, results and interpretation of cohort, case–control and cross-sectional studies. The checklist
comprises of 22 items that offer a basis for evaluating observational studies [23,24].
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Identification

Total records identified
(n=1802)

Records identified through
database searching
(n=1782)

Additional records identified through
hand search of reference
lists (n=20)

Screening

Potentially relevant records for more detailed
evaluation after scanning titles and abstracts
(n=533)

Records excluded
because they did not meet
the inclusion criteria
(n=391)

Records screened
(n=142)

Full-text articles assessed
for eligibility
(n=24)

Included

Eligibility

Full-text articles excluded,
with reasons: included
other models of follow-up
(n=123)

Cross-sectional (n=4), cohort (n=5), and
qualitative studies (n=4) (included and
evaluated using STROBE and Walsh
and Downe, respectively)
Systematic reviews (n=3)
(Total: n=16)

Randomised control studies included and
evaluated using CONSORT
(n=3)

Figure 1. PRISMA ﬂow diagram of the results of systematic review of general practitioner-led supportive care interventions

The Walsh and Downe recommendations are a set of iterative criteria that form a working framework for qualitative
research appraisal. This checklist comprises of eight stages that aid critical appraisal of study designs, methodology,
interpretation and transferability of results [25].
Selected articles were also reviewed by two other authors (MJ and AM) as a measure of inter-rater reliability. Differences in assessments by the reviewers were resolved by consensus when the full-text articles were reviewed.
The intervention, outcomes details and main conclusions were collected on a standard data sheet, which included
type of study, author, data, sample size and participation rates (Table 1).

Results
The reviewers reached a consensus on the remaining 19 articles, all of which were included in the review (Figure 1).
There were three randomised control trials, five cohort studies, four cross-sectional studies, four qualitative studies
and three systematic reviews. Due to variation in methodology of the studies and in how the findings were reported
and analysed, a meta-analysis was not feasible even for studies with similar outcome measures. Additionally, all the
studies included in this review were conducted in different countries with very different health care arrangements.
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Table 1. Results indicating type of GP involvement in cancer care
Type of study and
study setting

Reference

Study details

Type of GP
involvement

Extent of GP involvement

Randomised control
trial
Norway

Holtedahl
et al. [27]

Cancer site: Multiple sites
Length of follow-up: Six months
Sample size:
GP group n = 41, hospital n = 50
Survey response rate: GP group 88%,
hospital 90%

Formal involvement

Patients in the GP group received a
30-minute invited consultation with
the GP and an invitation to further
GP visits

Randomised control
trial
Denmark

Nielsen
et al. [28]

Cancer site: Multiple sites
Length of follow-up: Six months since
diagnosis
Sample size: GP group n = 121, hospital
n = 127
Questionnaire response rate: GP group
78%, hospital 64%

Formal involvement

Patients were encouraged to visit
their GP

Randomised control
trial
Denmark

Bergholdt
et al. [26]

Cancer site: Multiple sites
Length of follow-up: 14 months
Sample size: GP group n = 486, hospital
n = 469
Response rate: Overall response rate
reported = 71%

Formal involvement

GPs were encouraged to contact
the patients and facilitate the
rehabilitation process

Cross-sectional study
The USA

Forsythe
et al. [35]

Cancer site: Breast and colon
Sample size: PCPs n = 1,021, ONCs
n = 1130
Survey response rate: Not specified

Informal involvement

Patients attended a GP while still
receiving follow-up from the
specialists

Prospective longitudinal
study
Canada

Aubin
et al. [32]

Cancer site: Lung cancer
Length of follow-up: 18 months
Sample size: n = 395
Survey response rate: 56.8%

Informal involvement

Patients attended a GP while still
receiving follow-up from the
specialists

Retrospective cohort
study
The Netherlands

Roorda
et al. [33]

Cancer site: Breast
Sample size: Pts n = 185, Refgrp n = 585

Not specified

GPs were ‘informally’ involved in
the follow-up care of cancer
patients

Cross-sectional study
The USA

Haggstrom
et al. [34]

Cancer type: Colorectal cancer
Sample size: n = 303
Survey response rate: Not specified

Informal involvement

Patients attended a GP while still
receiving follow-up from the
specialists

Note: Dx = diagnosis, ONC = oncologist, Pts = patients, Refgrp = reference group (women without breast cancer)

Interventions and evaluation of general practitioner involvement
Studies where an intervention took place or was evaluated have been described below. In summary, 10 studies were
based on a framework, which sought information from patients on care (psychological, physical and social care) provided by their general practitioner. Patients’ rehabilitation needs were assessed directly by the general practitioner or
by cancer nurses/specialists and then relayed to the general practitioner in a letter.
In the Bergholdt et al. study, patients were invited for an interview about rehabilitation needs with a rehabilitation
coordinator at the hospital. The information from the hospital was sent to the general practitioner about individual
needs for rehabilitation and an encouragement of the general practitioner to contact the patient to offer his support
with rehabilitation [26].
In the Holtedahl et al. study, cancer patients were invited to a 30-minute consultation with the patient’s general practitioner, who was asked to let the patient tell about experiences as a cancer patient, and to tell the patient explicitly
that she or he would be welcome to contact the general practitioner whenever there was a question or a problem
related to their disease [27].
Two studies described a shared care programme between the general practitioner and the specialist: In the Nielsen
et al. study, a discharge summary letter detailing patient’s physical, psychological and social problems was posted to

This article is published in a peer reviewed section of the International Journal of Integrated Care

5

International Journal of Integrated Care – Volume 15, 8 June – URN:NBN:NL:UI:10-1-114828 – http://www.ijic.org/

the general practitioner. The summary also contained information about what the oncologists expected the general
practitioner to do, specific information about the patient’s type of cancer, treatment plans and prognosis as well as
general information about treatment of common side effects and pain. Names and phone numbers of the doctors
and nurses responsible for the patients were also attached [28].
In the Hall et al. study, patients were asked to attend general practitioners for follow-up appointments. Follow-up protocols and a system of specialist support were sent to the general practitioners by the treating specialist. General
practitioners were given an opportunity to shadow specialists as they conducted follow-up appointment at the hospital [29].
In the Sisler et al. study, colorectal cancer survivors who were sent a survey assessing their perceptions of continuity
of care around the time of discharge from the cancer centre. Health-related quality of life was also assessed as many
patients stated they had seen a general practitioner during their survivorship care [30].
Bowman et al. assessed primary care provider involvement in key activities measured by cancer survivors reports: if
primary care providers discussed with patients cancer-related problems and if these discussions resulted in tests
and procedures [31].
In five other studies, patients completed a survey on or data were analysed on either of the following: number of visits
to the family physician in the prior year; family physician’s, specialist’s and oncology team’s responsibility for cancer
care; family physician’s involvement in their care; perceived family physician’s actual and expected roles in various
aspects of care (coordination, psychosocial support, information transmission, symptom relief, preventive health);
and the family physician pattern of care [32–36].

Critical appraisal of the studies
Recruitment, randomisation and methods
Three randomised control trials with general practitioner interventions were identified [26–28]. All three studies fulfilled at least 22 of the 25 items in CONSORT and provided background details about the study objectives, eligible
participants and outcomes of interest. Reporting of the randomisation process was generally poor in most of the studies and details of the allocation concealment were not fully provided. Strategies used to generate allocation
sequences were only fully described by Bergholdt et al. [26] and Holtedahl et al. [27].
Of the five cohort and four cross-sectional studies, no studies fulfilled all criteria of the STROBE statement [23,24].
Six studies [30,32,33,35,37,38] provided clear information regarding the participants’ eligibility criteria, study setting,
locations and relevant dates, including periods of recruitment. In all the nine studies, descriptions of the study methods were often sparse and/or were either missing or partially satisfied. Details of the studies’ appraisal using CONSORT and STROBE (randomised control trials and observational studies, respectively) have been summarised in
Tables 2 and 3.
For the four qualitative studies [29,31,41,42], nearly all criteria outlined by Walsh and Downe [25] were met. The studies were contextualised by existing literature, details of the methods/design were consistent with research intent,
and the data collection strategies were apparent and appropriate. The authors also provided data to support interpretation and elements of study relevance and transferability. However, the description of the analytical approach i
n these studies was unclear. Details of how the subjective meanings of participants were portrayed or handled
and in what ways the deviant data were sought were missing. A critical review of the qualitative studies has been
summarised in Table 4.
Overview of research findings
The outcomes and results of the type of interventions are summarised in Table 1 for randomised control trials and
cohort and cross-sectional studies. The two following main themes emerged when data were synthesised:
. Outcome of care was generally reported as any progress in patients’ psychosocial and physical functioning (or an overall
improvement in patients’ quality of life), detection of recurrence, management of comorbidities and preventive health.
. Perspectives of care were reported as patients’ satisfaction with the care provided by the general practitioner or health professionals’ views of the general practitioners’ role in providing post-treatment cancer.
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Table 2. Critical review of randomised control trials assessing GP involvement in cancer care using CONSORT

Section/Topic

Title and abstract

Item
no.

Checklist Item

Bergholdt
et al. [26]

Holtedahl
et al. [27]

Nielsen
et al. [28]

Reported on
page no.

Reported on
page no.

Reported on
page no.

1a

Identified as a randomised trial in the title

1

949

263

1b

Structured summary of trial design, methods,
results and conclusions (for specific guidance,
see CONSORT for abstracts)

1

949

263

2a

Scientific background and explanation of
rationale

2

949

263

2b

Specific objectives or hypotheses

2

949

263

3a

Description of trial design (such as parallel or
factorial), including allocation ratio

2

Not clarified

Not clarified

3b

Important changes to methods after trial
commencement (such as eligibility criteria), with
reasons

Not clarified

Not clarified

Not clarified

4a

Eligibility criteria for participants

2

950

264

4b

Settings and locations where the data were
collected

2

950

263

Interventions

5

The interventions for each group with sufficient
details to allow replication, including how and
when they were actually administered

3

950

263–264

Outcomes

6a

Completely defined pre-specified primary and
secondary outcome measures, including how
and when they were assessed

4

950

264

6b

Any changes to trial outcomes after the trial
commenced, with reasons

Not clarified

Not clarified

Not clarified

7a

How sample size was determined

4

952

264

7b

When applicable, explanation of any interim
analyses and stopping guidelines

Not clarified

Not clarified

Not clarified

8a

Method used to generate the random allocation
sequence

4

950

265

8b

Type of randomisation, and details of any
restriction (such as blocking and block size)

4

Not clarified

265

Allocation concealment
mechanism

9

Mechanism used to implement the random
allocation sequence (such as sequentially
numbered containers), describing any steps
taken to conceal the sequence until
interventions were assigned

4

950

265

Implementation

10

Who generated the random allocation
sequence, who enrolled participants, and who
assigned participants to interventions

4

950

265

11a

If done, who was blinded after assignment to
interventions (for example, participants, care
providers or those assessing outcomes)
and how

4

950

265

11b

If relevant, description of the similarity of
interventions

Not clarified

Not clarified

Not clarified

Introduction
Background and
objectives

Methods
Trial design

Participants

Sample size

Randomisation
Sequence generation

Blinding
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Table 2. (Continued)

Section/Topic

Statistical methods

Item
no.

Checklist Item

Bergholdt
et al. [26]

Holtedahl
et al. [27]

Nielsen
et al. [28]

Reported on
page no.

Reported on
page no.

Reported on
page no.

12a

Statistical methods used to compare groups for
primary and secondary outcomes

4

952

264

12b

Methods for additional analyses, such as
subgroup analyses and adjusted analyses

4

952

Partially clarified

13a

For each group, the numbers of participants who
were randomly assigned, received intended
treatment, and were analysed for the primary
outcome

4

951

266

13b

For each group, losses and exclusions after
randomisation, together with reasons

2

951

266

14a

Dates defining the periods of recruitment and
follow-up

4

Partially clarified

265

14b

Why the trial ended or was stopped

Not applicable

Not applicable

Baseline data

15

A table showing baseline demographic and
clinical characteristics for each group

Numbers analysed

16

Outcomes and estimation

Results
Participant flow (a
diagram is strongly
recommended)

Recruitment

Not applicable
4

952

265

For each group, the number of participants
(denominator) included in each analysis and
whether the analysis was by original assigned
groups

5–7

953–954

265, 267–270

17a

For each primary and secondary outcome, the
results for each group and the estimated effect
size and its precision (such as 95% confidence
interval)

5–7

953–954

267–270

17b

For binary outcomes, presentation of both
absolute and relative effect sizes is
recommended

Ancillary analyses

18

Results of any other analyses performed,
including subgroup analyses and adjusted
analyses, distinguishing pre-specified from
exploratory

5–7

953–954

Partially clarified

Harms

19

All important harms or unintended effects in
each group (for specific guidance, see
CONSORT for harms)

Not clarified

Not clarified

Not clarified

Limitations

20

Trial limitations, addressing sources of potential
bias, imprecision and (if relevant) multiplicity of
analyses

6

955

268

Generalisability

21

Generalisability (external validity and
applicability) of the trial findings

6

955

268

Interpretation

22

Interpretation consistent with results, balancing
benefits and harms, and considering other
relevant evidence

6-Aug

955

267–270

Registration

23

Registration number and name of trial registry

Not clarified

Not clarified

Not clarified

Protocol

24

Where the full trial protocol can be accessed, if
available

Not clarified

Not clarified

Not clarified

Funding

25

Sources of funding and other support (such as
supply of drugs) and role of funders

8

955

271

Not applicable

Not applicable

Not clarified

Discussion

Other information

This article is published in a peer reviewed section of the International Journal of Integrated Care

8

Y

(b) In the abstract, provide an informative and balanced
summary of what was done and what was found

Y
Y
N
N/A

Give the eligibility criteria, and the sources and methods of
selection of participants. Describe methods of follow-up

Clearly define all outcomes, exposures, predictors,
potential confounders and effect modifiers. Give
diagnostic criteria, if applicable

For each variable of interest, give sources of data and
details of methods of assessment (measurement).
Describe comparability of assessment methods if there
was more than one group

Describe any efforts to address potential sources of bias

Explain how quantitative variables were handled in the
analyses. If applicable, describe which groupings were
chosen and why

Explain how the study size was reached

(a) Describe all statistical methods, including those used
to control for confounding

(b) Describe any methods used to examine subgroups
and interactions

(c) Explain how missing data were addressed

(d) Cohort study: If applicable, explain how loss to followup was addressed

Participants

Variables

Data sources/
measurement

Bias

Quantitative variables

This article is published in a peer reviewed section of the International Journal of Integrated Care

Sample size

Statistical methods

Y

Y

N/A

N

Y

Y

N

Y

Y

N

Y

Y

N

Y

Y

N

Y

Y

Y

Y

Y

Roorda
et al.
[33]

N

Y

Y

Describe the setting, locations and relevant dates,
including periods of recruitment, exposure, follow-up and
data collection

Setting

N

Study design mentioned earlier in the paper

Present key elements of the study design early in the
paper

Y

State specific objectives, including any pre-specified
hypotheses

Objectives

Study design

Y

Explain the scientific background and rationale for the
investigation being reported
Y

Y

(a) Indicate the study's design with a commonly used term
in the title or abstract

Descriptor

Background

Introduction

Title and abstract

Item

Sisler
et al.
[30]

Table 3. Critical review of observational studies assessing GP involvement in cancer care using STROBE

N/A

N

Y

Y

N

Y

N

Y

Y

Y

Y

N

Y

Y

Y

Y

N

Haggstrom
et al.
[34]

N

N

N

N

N

Y

N

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

Aubin
et al.
[32]

Y

N/A

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Forsythe
et al.
[35]

N/A

N/A

Y

Y

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

N

Earle
et al.
[13]

N/A

N

Y

Y

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Lundstrom
et al.
[37]

N/A

N/A

Y

Y

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Snyder
et al.
[39]

N/A

Y

Y

Y

Y

Y

N

Y

Y

Y

Y

Y

Y

Y

Y

Y

Y

Mahboubi
et al.
[40]
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Other analyses

Main results

Y
N/A

(b) Report category boundaries when continuous
variables were categorised

(c) If relevant, consider translating estimates of relative
risk into absolute risk for a meaningful time period

Y

Y

Y

(a) Give unadjusted estimates and, if applicable,
confounder-adjusted estimates and their precision (e.g.
95% confidence interval). Make clear which confounders
were adjusted for and why they were included

Report other analyses done-e.g. analyses of subgroups
and interactions, and sensitivity analyses

Y

Y

Cross-sectional study: Report numbers of outcome events
or summary measures

Y

N/A

Y

N/A

N/A

Case-control study: Report numbers in each exposure
category, or summary measures of exposure

N/A

N/A

N/A

N

Y

Y

Y

Y

N

N/A

N/A

Roorda
et al.
[33]

Cohort study: Report numbers of outcome events or
summary measures over time

N/A

(c) Cohort study: Summarise follow-up time (e.g. average
and total amount)

Outcome data

Y

(b) Indicate number of participants with missing data for
each variable of interest

Data

Y

(c) Consider using a flow diagram

(a) Give characteristics of study participants (e.g.
demographic, clinical and social) and information on
exposures and potential confounders

Y
N

(b) Give reasons for non-participation at each stage

Y

(e) Describe any sensitivity analyses

Y

Y

Cross-sectional study: If applicable, describe analytical
methods taking account of sampling strategy

(a) Report numbers of individuals at each stage of studye.g. numbers potentially eligible, examined for eligibility,
confirmed eligible, included in the study, completing
follow-up, and analysed

N/A

Case–control study: If applicable, explain how matching of
cases and controls was addressed

Descriptor

Descriptive

Participants

Results

Item

Sisler
et al.
[30]

Table 3. (Continued)

N

N

Y

Y

Y

N/A

N/A

N/A

N

Y

Y

N

Y

N

N

N/A

Haggstrom
et al.
[34]

Y

N

Y

Y

N/A

N/A

Y

Y

N

Y

Y

Y

Y

N

N/A

N/A

Aubin
et al.
[32]

Y

Y

Y

Y

Y

N/A

N/A

N/A

Y

Y

N

Y

Y

N

Y

N/A

Forsythe
et al.
[35]

Y

Y

N/A

Y

N/A

N/A

Y

Y

N

Y

N/A

N/A

Y

N

N/A

N/A

Earle
et al.
[13]

Y

Y

Y

Y

Y

N/A

N/A

N/A

N

Y

Y

Y

Y

N

Y

N/A

Lundstrom
et al.
[37]

Y

Y

Y

Y

N/A

N/A

Y

Y

N

Y

N

N/A

Y

Y

N/A

N/A

Snyder
et al.
[39]

Y

Y

Y

Y

N/A

N/A

Y

Y

Y

Y

N

N/A

Y

N/A

N/A

N/A

Mahboubi
et al.
[40]
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Discuss limitations of the study, taking into account
sources of potential bias or imprecision

Key: Y, item clarified; N, item not clarified; N/A, item not applicable to this study

Total

Funding

Give the source of funding and the role of the funders for
the present study and, if applicable, for the original study
on which the present article was based

Discuss the generalisability (external validity) of the study
results

Generalisability

Other information

Give a cautious overall interpretation of results
considering objectives, limitations, multiplicity of analyses,
results from similar studies, and other relevant evidence

Interpretation

Discuss direction and magnitude of any potential bias

Summarise key results with reference to study objectives

Limitations

Descriptor

Key results

Discussion

Item

27/31

N

Y

Y

Y

Y

Sisler
et al.
[30]

24/31

Y

Y

Y

Y

Y

Roorda
et al.
[33]

Table 3. (Continued)

21/33

Y

N

Y

Y

Y

Haggstrom
et al.
[34]

24/34

Y

Y

Y

Y

Y

Aubin
et al.
[32]

31/33

Y

Y

Y

Y

Y

Forsythe
et al.
[35]

24/30

N

Y

Y

Y

Y

Y

Earle
et al.
[13]

30/34

Y

Y

Y

Y

Y

Y

Lundstrom
et al.
[37]

30/33

Y

Y

Y

Y

Y

Y

Snyder
et al.
[39]

30/32

Y

Y

Y

Y

Y

Y

Mahboubi
et al.
[40]

International Journal of Integrated Care – Volume 15, 8 June – URN:NBN:NL:UI:10-1-114828 – http://www.ijic.org/

This article is published in a peer reviewed section of the International Journal of Integrated Care

11

International Journal of Integrated Care – Volume 15, 8 June – URN:NBN:NL:UI:10-1-114828 – http://www.ijic.org/

Table 4. Critical review of qualitative studies assessing GP involvement in cancer care using Walsh and Downie criteria

Stages
Scope and
purpose

Design

Hudson
et al.
[41]

Hall
et al.
[29]

Murchie
et al.
[42]

Anvik
et al.
[44]

Clarity of focus demonstrated

Y

Y

Y

Y

Explicit purpose given, such as descriptive/
explanatory intent, theory building and hypothesis
testing

Y

Y

Y

Y

Link between research and existing knowledge
demonstrated

Y

Y

Y

Y

Study thoroughly
contextualised by existing
literature

Evidence of systematic approach to literature review,
location of literature to contextualise the findings,
or both

Y

Y

Y

Y

Method/design apparent and
consistent with research intent

Rationale given for use of qualitative design

Y

Y

Y

Y

Discussion of why particular method chosen is most
appropriate, sensitive and relevant to research
questions and aims

Y

Y

Y

Y

Discussion of epistemological/ontological grounding

Y

Y

Y

Y

Were data collection methods appropriate for the type
of data required and the specific qualitative method?

Y

Y

Y

Y

Were they likely to capture the complexity/diversity of
experience and illuminate context in sufficient detail?

Y

Y

Y

Y

N/A

Y

Y

Y

Selection criteria detailed, and description of how
sampling was undertaken

Y

Y

Y

Y

Justification for sampling strategy given

N

Y

Y

N

Thickness of description likely to be achieved from
sampling

Y

Y

Y

Y

Any disparity between planned and actual sample
explained

Y

Y

Y

N

Approach made explicit (e.g. thematic distillation,
constant comparative method, grounded theory)

Y

Y

Y

Y

Was it appropriate for the qualitative method chosen?

Y

Y

Y

Y

Were data managed by software package or by hand,
and why?

Y

Y

Y

Y

Discussion of how coding systems/conceptual
frameworks evolved

Y

Y

Y

Y

How was context of data retained during analysis?

Y

Y

Y

Y

Evidence that the subjective meanings of participants
were portrayed

N

Y

Y

Y

Evidence of more than one researcher involved in
stages, if appropriate to epistemological/theoretical
stance

Y

Y

Y

Y

Did research participants have any involvement in
analysis (e.g. member checking)?

Y

Y

Y

Y

Evidence provided that data reached saturation, or
discussion and rationale if it did not

Y

Y

Y

Y

Evidence that deviant data were sought, or
discussion and rationale if they were not

N

N

Y

N

Description of social/physical and interpersonal
contexts of data collection

Y

Y

Y

Y

Essential criteria
Clear statement of and
rationale for research
questions, aims and purposes

Data collection strategy
apparent and appropriate

Specific prompts

Was triangulation of data sources used, if
appropriate?
Sampling
strategy

Analysis

Interpretation

Sample and sampling method
appropriate

Analytic approach appropriate

Context described and taken
account of in interpretation
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Table 4. (Continued)

Stages

Essential criteria
Clear audit trail given

Data used to support
interpretation

Reflexivity

Ethical
dimensions

Relevance
and
transferability

Researcher reflexivity
demonstrated

Demonstration of sensitivity to
ethical concerns

Relevance and transferability
evident

Hudson
et al.
[41]

Hall
et al.
[29]

Murchie
et al.
[42]

Anvik
et al.
[44]

Evidence that researcher spent time ‘dwelling with
the data’, interrogating it for competing or alternative
explanations of phenomena

Y

Y

Y

Y

Sufficient discussion of research processes so that
others can follow the ‘decision trail’

Y

Y

Y

Y

Extensive use of field notes entries/verbatim
interview quotations in discussion of findings

Y

Y

Y

Y

Clear exposition of how interpretation led to
conclusions

Y

Y

Y

Y

Discussion of relationship between researcher and
participants during fieldwork

Y

Y

Y

Y

Demonstration of researcher's influence on stages of
research process

Y

Y

Y

Y

Specific prompts

Evidence of self-awareness/insight

Y

Y

Y

Y

Documentation of effects of the research on
researcher

N

N

Y

N

Evidence of how problems/complications were
managed

Y

Y

Y

Y

Ethical committee approval granted

Y

Y

Y

Y

Clear commitment to integrity, honesty, transparency,
equality and mutual respect in relationships with
participants

Y

Y

Y

Y

Evidence of fair dealing with all research participants

Y

Y

N

Y

Record of dilemmas and how they were resolved in
relation to ethical issues

Y

Y

Y

Y

Documentation of how autonomy, consent,
confidentiality and anonymity were managed

Y

Y

Y

Y

Sufficient evidence for typicality specificity to be
assessed

Y

Y

Y

Y

Analysis interwoven with existing theories and other
relevant explanatory literature drawn from similar
settings and studies

Y

Y

Y

Y

Discussion of how explanatory propositions/
emergent theory may fit other contexts

Y

Y

Y

Y

Limitations/weaknesses of study clearly outlined

Y

Y

Y

Y

Clearly resonates with other knowledge and
experience

Y

Y

Y

Y

Results/conclusions obviously supported by
evidence

Y

Y

Y

Y

Interpretation plausible and ‘makes sense’

Y

Y

N

Y

Provides new insights and increases understanding

Y

Y

Y

Y

Significance for current policy and practice outlined

Y

Y

Y

Y

Assessment of value/empowerment for participants

Y

Y

Y

Y

Outlines further directions for investigation

Y

Y

Y

Y

Comment on whether aims/purposes of research
were achieved

Y

Y

Y

Y

49/50

49/51

49/51

47/51

Total
Key: Y, item clarified; N, item not clarified
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Outcomes of care
Physical and psychological outcomes and quality of life
Seven studies reported general practitioners’ supportive role in providing post-treatment cancer care in the context
of ongoing specialists’ care [26–29,32,35,43]. There were mixed results reported on quality of life benefits to
patients.
Holtedahl et al. [27], in a randomised control trial investigating whether patients benefit from increased contact
with their general practitioner after cancer treatment, showed that for the 81 patients who answered two sets of
quality of life questionnaires, there was an improvement at 6 months in the physical, role and social function
status (p = 0.032, 0.004 and 0.032, respectively), but this effect on the quality of life was only observed when
frequent contacts occurred. For the 58 patients who answered the overall care questionnaire at randomisation
and at 6 months, there was a lack of a significant improvement in their perception about care provided by
their general practitioner (p = 0.060). However, this lack of a significant difference may have occurred due to
the study inclusion criteria. The number of excluded patients was high in this study and most patients had stable
disease (73 out of 78), and thus may have had little need for increased general practitioner support at the time of
inclusion.
Bergholdt et al. [26] examined the involvement of general practitioners in cancer rehabilitation, with the primary outcome being the global health status of patients after 6 months. They allocated 281 patients to the intervention group
and 297 to the control group (hospital care only) and found that the intervention had no statistically significant impact
on the primary outcome. Adjustment for age and sex showed results similar to the unadjusted analysis. Overall, this
intervention had a limited effect on the quality of life and psychological distress of patients but had a positive impact
on patients’ evaluation of co-operation between primary and secondary health care sectors. A quality analysis of this
study based on CONSORT revealed an adequate sample size. Although this study was powered (80%; α’ = 0.05,
n = 144) to detect differences between the groups on the primary outcome, process evaluation measures such as
general practitioner proactivity and patient participation were not done and this may have affected the quality of
life results. To improve the quality of life outcome, Bergholdt et al. [26] recommended the development of screening
tools that support identification of patients with special needs and initiatives that support the general practitioners in
undertaking a proactive role for patients with cancer needs.
Nielsen et al. [28] reported results similar to Bergholdt et al. [26]. In this study, a discharge summary letter detailing
patients’ potential or current physical, psychological and social problems was sent to the general practitioner at the
end of the treatment period by the oncologists. Patients in the intervention group were encouraged to visit their general practitioner. Patients’ attitudes to the health care services, reports on contacts with the general practitioner,
health-related quality of life and performance status were evaluated at baseline and 3 and 6 months thereafter.
The results of patients’ assessments of their health-related quality of life using the EORTC QLQ-C30 measure
showed no statistically significant differences between the intervention and control groups, but there were improvements in quality of care offered in the intervention group.
Preventive health and management of other chronic illnesses
Earle and Neville in a retrospective cohort study analysed chronic comorbidities and preventive health care of cancer
patients being managed by both primary care physicians and specialists. In this study, 50% of survivors (7465
patients) continued to see an oncologist in follow-up and 8% of these survivors (587 patients) saw only an oncologist.
In all categories of care, patients who were followed by both oncologists and primary care physicians received the
highest proportion of recommended care for the management of cancer, chronic illnesses and preventive health, followed by patients who were followed by primary care physicians. Patients who were followed only by oncologists
received significantly worse preventive care compared with patients who also had a primary care physician. Survivors who did not receive care from an oncologist were less likely to undergo cancer-related procedures of surveillance colonoscopy (27.6% vs. 46.7%) and mammography (26.5% vs. 31.3%) compared with patients who saw an
oncologist. Conversely, the subset of patients who were seen only by primary care physicians was more likely to
receive influenza vaccination (55.2% vs. 43.6%), cervical screening (14.7% vs. 8.2%) and bone densitometry
(3.9% vs. 1.1%) compared with patients who were followed only by an oncologist [13].
In an analysis by Haggstrom et al. [34] on the type of doctor speciality that cancer patients frequently visited during
cancer follow-up care other than the oncologist, 16% of those on follow-up (n = 303) reported visiting a general practitioner. Of these, 70% had two or three other medical conditions they were being followed up for in primary care [34].
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In this study, survivors were asked if they received follow-up medical tests to check for signs of other health conditions, if their doctor discussed preventive health issues such as lifestyle changes, type of diet or physical exercise.
The results of this study survivors of colorectal cancer who most often saw oncologists were still significantly more
likely than those who saw primary care providers to report seeing a doctor for follow-up tests and less likely to
receive a physical exam. In terms of health promotion activities, colorectal cancer survivors who most often saw primary care physicians for follow-up cancer care were significantly more likely than survivors who saw specialists to
report that their follow-up doctor helped with lifestyle (83% vs. 63%; p = 0.015) and discussed diet (70% vs. 48%;
p = 0.005). In models adjusting for patient characteristics, oncologists were significantly less likely than primary
care providers to discuss disease prevention, provide help with lifestyle and discuss diet [34].
Anvik et al. [44] explored the role of a general practitioner in post-treatment cancer care of patients recently treated
and reported that patients trust their general practitioner to provide competent care, especially when they have more
complex health care needs besides cancer.

Perspectives of Care
Patients’ perspectives
Satisfaction with care was reported both qualitatively and quantitatively in six studies [27,28,31,41,43,44]. Holtedahl
et al. [27] reported that there was a non-significant tendency towards higher satisfaction among patients whose general practitioners were involved in their care. The improvement in scores on perceptions of patients regarding their
overall cancer care was evident between randomisation and 6 months (score from 55.2 to 58.9; p = 0.060). Furthermore, when the authors conducted a subgroup analysis comparing those patients treated with curative intent and
those offered palliative treatment, this tendency was confirmed for patients treated with curative intent (62.15 vs.
46.38; p = 0.035) [27].
In an analysis done by Aubin et al. [32] on patients’ perceived gap between actual and expected family physician
involvement in cancer care at all phases of cancer, patients preferred their family doctor to be involved in all aspects
of care.
Similarly, Nielsen et al. [28] reported a statistically significant difference between the intervention and control groups
at 3 months when patients’ attitudes towards co-operation (between general practitioner and oncologist) and their
feeling of ‘not being left in limbo’ were assessed (p = 0.025). A subgroup analysis of these variables showed that
men in the general practitioner-integrated programme felt less ‘left in limbo’ (p = 0.031) as did the younger age group
(18–49 years) at both 3 and 6 months (p = 0.024 and p = 0.031), respectively. In this study, male gender (p = 0.007)
or younger age (p = 0.029) were predictors of increased contact visits with a general practitioner and in the ability of
the general practitioner to manage post-treatment cancer care.
Qualitative studies also reported comparable results. Hall et al. [29] modelled a shared care model and explored the
views of potential patients and opinions/experiences of patients/doctors in the model, while Hudson et al. [41]
explored survivor preferences of the shared care model.
Hall et al. [29] and Hudson et al. [41] revealed that patients were more receptive of general practitioner involvement
in post-treatment cancer care if they were confident that the general practitioner had received extra training and support from the hospital. The shared care model was also seen as favourable to participants because of reduced waiting time and parking fees. In particular, this model was reported to be valuable to those living in the regional areas
because of reduced number of hospital visits and travel logistics [29].
Five studies reported continued patient contact with the general practitioner while patients were on follow-up in the
hospital [28,31,32,34,37]. Aubin et al. [32,38], Bowman et al. [31] and Lundstrøm et al. [37] assessed family physician involvement in cancer care and found that large proportions (88%, 62% and 35%, respectively) of patients continued to visit their general practitioner informally throughout their cancer journey despite being followed up in the
hospital by the specialist.
Similarly, Nielsen et al. [28] noted that patients randomised to the shared care group had an increased number of
visits to their general practitioner at 3 and 6 months (p = 0.049 and p = 0.042, respectively).
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Health professionals’ perspectives
Three studies [29,35,44] included in this review evaluated the health professionals’ views/experiences of general
practitioner involvement in post-treatment cancer care. Forsythe et al. [35], in a survey of oncologists and general
practitioners, examined perceptions of shared responsibility for psychological follow-up of cancer patients. In this
study, general practitioners were more likely to report shared provision for the management of physical symptoms
and sole provision for health promotion and psychosocial care compared to oncologists. On the other hand, oncologists reported a shared approach regarding provision of patient psychosocial care (p < 0.001). Among the aspects
of psychosocial care provided by general practitioners were treatment of sexual dysfunction, depression and anxiety
[35]. Similarly, Wind et al. [45] explored experiences of surgeons in addressing cancer-related psychosocial problems and other non-cancer-related physical problems and reported that over 40% of the surgeons felt that these
issues were beyond their field of experience.
Wind et al. and Anvik et al. reported that both general practitioners and surgeons were confident that the general
practitioners can handle post-treatment cancer care in patients with a low risk of recurrence (p = 0.004) [45] and
that the general practitioner has a place in the follow-up of many patients with cancer, including the initial phase after
treatment [44].
Hall et al. [29], in a qualitative study exploring general practitioners’ and patients’ experiences/opinions of general
practitioner involvement in post-treatment care, reported that general practitioners felt that their own clinical skills
were improved when they received support and training. In this study, clinical skills of general practitioners were
enhanced by attending training seminars and shadowing the specialist at the cancer clinics.

Discussion and Conclusion
This review of the literature reported the outcomes of general practitioner involvement in post-treatment care alongside hospital care for cancer. Nearly all reviewed studies indicated that involving the general practitioner in the care
of patients alongside specialist visits is possible and acceptable to patients. Evidence from the reviewed papers suggested that it is feasible to involve general practitioners in the care of cancer patients, provided they are equipped
with the necessary skills.
This review indicated that both specialists and general practitioners were confident that the general practitioner was
able to take a role in post-treatment cancer care. Most general practitioners are prepared to take a more prominent
role in post-treatment cancer contingent on good specialist support. The reviewed studies showed no differences
between the general practitioner and the specialist in management of patients’ physical health and general practitioners were better at recognising psychosocial issues. Patient contact with the general practitioner for supportive
care was significantly associated with identification and management of psychosocial issues. Overall, general practitioners reported greater involvement in the management of psychosocial issues and shared management with the
specialist on physical symptoms.
There were conflicting results from studies that examined quality of life. Overall, general practitioner involvement in
follow-up care was associated with improvement in physical and social well-being of patients following cancer treatment. In studies where general practitioner involvement did not result in statistically significant improvement in quality of life, patients reported enhanced quality and coordination of care. In fact, patients who had their general
practitioner involved and had other concomitant health conditions reported greater continuity of care and a less fragmented approach to managing their health.
Caution should however be exercised when interpreting such results as the study periods were relatively short in
some of the reports, the measures used to assess quality of life were different and the reporting quality of each study
was variable. For all studies, there were many aspects of methodological quality identified. Overall, regarding the
quality of life aspect, the quality of data was generally poor and no conclusive evidence can be drawn from the collated data or narratives.
Given that not all studies included in this review performed a subgroup analysis on the effect of general practitioner
involvement on patient outcomes with different types of cancer, it is plausible that the effects may differ if this model
was to be applied to specific cancers. Most studies reported an overall effect of general practitioner involvement on
patient outcomes (physical, psychological and social) for all cancers combined.
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The reviewed studies did not provide strong evidence of the patient’s role in driving the delivery of care. Most studies
either mentioned patient proactive approaches as a recommendation in their summary of findings or in the methodology. In some studies, patients were encouraged to visit their general practitioner if they perceived a need to do so,
and in others the general practitioner was furnished with an assessment of the patient’s condition and was encouraged to invite the patient for a consultation. The quality of measures used to aid general practitioner consultation was
not standardised. In some studies, general practitioners used broad questions to assess the general well-being of
the patient, whereas in other studies the nurse coordinator assessed the needs of the patients, sent the report to
the general practitioner and encouraged the general practitioners to contact patients. The deployment of a validated
questionnaire detailing possible needs of the patients and how this assessment was used to encourage a consultation with the general practitioner was limited. In fact, Bergholdt et al. [26] recommended the use of a screening tool or
a decision support tool to identify and address patient needs.

Study Strengths and Limitations
The small number of studies identified for this review may be due to a number of reasons. Ongoing involvement of
the general practitioner in post-treatment cancer care was not clearly described in the literature. In some cases, this
was described as ‘formal’ shared care where different roles of the general practitioner and those of the specialist
were clearly delineated, whereas in other studies this was described as ‘informal’ shared care where patients continued to visit their general practitioner informally while still on scheduled visits with the specialist. However, database searches were supplemented by a hand search from the list of references of the identified papers and
systematic reviews.
Finally, heterogeneity of the study methods, outcome measures and analytical approach of various studies meant
that no data could be pooled in a meta-analysis.

Recommendations
To improve patient outcomes in this approach, the design and testing of validated measures that support identification of patients who may benefit from general practitioner involvement while still on ongoing care from the specialist
may be helpful. Additionally, devising and deploying initiatives that encourage and facilitate patients to consult their
general practitioner first about what they believe are the needs or symptoms of recurrence should be considered.
Applying this model of post-treatment cancer care to patients with a specified cancer would clarify whether the outcomes would be different.
This review of the literature demonstrates that general practitioner involvement alongside specialist care for cancer
patients has not been robustly explored despite some of the studies concluding that they are feasible and acceptable
to patients.
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